DexCom, Inc. (NASDAQ:DXCM) Shares Sold by Thrivent Financial for Lutherans

Thrivent Financial for Lutherans lessened its holdings in shares of DexCom, Inc. (NASDAQ:DXCM) by 4.9% in the second quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 217,828 shares of the medical device company’s stock after selling 11,205 shares during the quarter. Thrivent Financial for Lutherans owned 0.05% of DexCom worth $24,697,000 as of its most recent filing with the SEC.

Several other large investors also recently bought and sold shares of the company. Vanguard Group Inc. grew its position in DexCom by 0.3% in the first quarter. Vanguard Group Inc. now owns 44,603,745 shares of the medical device company’s stock valued at $6,186,539,000 after acquiring an additional 136,282 shares in the last quarter. Capital Research Global Investors grew its position in DexCom by 21.4% in the fourth quarter. Capital Research Global Investors now owns 15,296,032 shares of the medical device company’s stock valued at $1,898,085,000 after acquiring an additional 2,695,296 shares in the last quarter. Sands Capital Management LLC grew its position in DexCom by 10.2% in the fourth quarter. Sands Capital Management LLC now owns 15,058,806 shares of the medical device company’s stock valued at $1,868,647,000 after acquiring an additional 1,398,136 shares in the last quarter. Capital World Investors grew its position in DexCom by 130.7% in the fourth quarter. Capital World Investors now owns 9,278,685 shares of the medical device company’s stock valued at $1,151,392,000 after acquiring an additional 5,256,092 shares in the last quarter. Finally, Artisan Partners Limited Partnership grew its position in DexCom by 164.8% in the fourth quarter. Artisan Partners Limited Partnership now owns 5,900,308 shares of the medical device company’s stock valued at $732,169,000 after acquiring an additional 3,672,471 shares in the last quarter. Institutional investors and hedge funds own 97.75% of the company’s stock.

Insider Buying and Selling

In related news, EVP Michael Jon Brown sold 659 shares of DexCom stock in a transaction dated Friday, June 28th. The stock was sold at an average price of $114.29, for a total value of $75,317.11. Following the transaction, the executive vice president now owns 66,901 shares of the company’s stock, valued at approximately $7,646,115.29. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other DexCom news, EVP Sadie Stern sold 426 shares of the firm’s stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $69.15, for a total transaction of $29,457.90. Following the completion of the sale, the executive vice president now directly owns 75,451 shares in the company, valued at approximately $5,217,436.65. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Michael Jon Brown sold 659 shares of the firm’s stock in a transaction dated Friday, June 28th. The stock was sold at an average price of $114.29, for a total value of $75,317.11. Following the sale, the executive vice president now owns 66,901 shares of the company’s stock, valued at $7,646,115.29. The disclosure for this sale can be found here. In the last quarter, insiders have sold 2,483 shares of company stock valued at $201,708. 0.30% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

DXCM has been the subject of several recent research reports. Royal Bank of Canada lowered their price objective on shares of DexCom from $165.00 to $145.00 and set an “outperform” rating for the company in a research report on Friday, July 26th. Robert W. Baird increased their target price on DexCom from $80.00 to $82.00 and gave the company a “neutral” rating in a research note on Monday, August 5th. Oppenheimer reduced their target price on DexCom from $150.00 to $115.00 and set an “outperform” rating for the company in a research note on Friday, July 26th. Baird R W cut DexCom from a “strong-buy” rating to a “hold” rating in a research note on Friday, July 26th. Finally, StockNews.com cut DexCom from a “buy” rating to a “hold” rating in a research note on Monday, June 10th. Seven research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, DexCom has an average rating of “Moderate Buy” and a consensus price target of $112.25.

DexCom Trading Down 1.0 %

Shares of DXCM opened at $69.70 on Tuesday. The business’s 50-day moving average price is $77.32 and its 200 day moving average price is $108.93. The stock has a market capitalization of $27.72 billion, a P/E ratio of 44.97, a P/E/G ratio of 2.12 and a beta of 1.18. DexCom, Inc. has a 1-year low of $62.34 and a 1-year high of $142.00. The company has a current ratio of 2.82, a quick ratio of 2.48 and a debt-to-equity ratio of 1.00.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings results on Thursday, July 25th. The medical device company reported $0.43 earnings per share for the quarter, topping analysts’ consensus estimates of $0.39 by $0.04. The firm had revenue of $1 billion for the quarter, compared to analysts’ expectations of $1.04 billion. DexCom had a return on equity of 31.41% and a net margin of 16.95%. DexCom’s revenue was up 15.3% on a year-over-year basis. During the same quarter last year, the business posted $0.34 EPS. Analysts expect that DexCom, Inc. will post 1.69 earnings per share for the current year.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.